No Data
Shareholders of Kerenbo Tai Biotech (06990) have deposited Stocks into China Securities Depository and Clearing in Hong Kong, with a Market Cap of 7.835 billion HKD.
On April 25, shareholders of Kelun-Botai Biological (06990) deposited Stocks into Hong Kong Securities Clearing Company, with a Market Cap of 7.835 billion Hong Kong dollars, accounting for 19.34%.
SKB BIO-B (06990.HK): The company has completed the full circulation of Listed in Hong Kong.
Globe News on April 25丨SKB BIO-B (06990.HK) announced that the Board of Directors is pleased to declare that a total of 25,421,196 domestic shares have been successfully converted as of April 25, 2025, and the conversion of H shares will commence listing on the Stock Exchange at 9:00 AM on April 28, 2025.
[Brokerage Focus] Ping An Securities initially assigns a "Recommended" rating to Kelun-Botai Biotech (06990), noting the smooth transition of its integrated research and sales transformation.
Jinwu Financial News | Ping An Securities research pointed out that Kelun Botai Biology (06990) will primarily derive its income in 2024 from authorized collaborations and product sales, with total revenue of 1.93 billion yuan (+25.5%), of which 1.86 billion yuan comes from authorized collaborations; costs are controllable, with R&D expenses reaching 1.2 billion yuan (+17%) and administrative expenses at 0.163 billion yuan (-10.2%). Due to team building and academic promotion expenses, sales expenses will amount to 0.183 billion yuan. The company is expected to have a net loss of 0.267 billion yuan in 2024, an improvement of 53.5% year-on-year. As of the end of 2024, the company's current...
The Innovative Drugs Concept is generally rising, INNOVENT BIO (01801) increased by 7%. Institutions indicate that the actual geopolitical risks in the Sector are relatively low.
Jinwu Financial News | The Innovative Drugs sector generally rose, with Hutchmed (China) (00013) up by 3.92%. The company will announce data at the American Association for Cancer Research (AACR) 2025 annual meeting. In addition, AKESO (09926) rose by 7.1%, INNOVENT BIO (01801) rose by 7%, SKB BIO-B (06990) rose by 4.76%, KEYMED BIO-B (02162) rose by 3.41%, and 3SBIO (01530) rose by 3.28%. Sinolink's Research Reports stated that the rapidly changing external tariff environment provides the pharmaceutical sector with good anti-risk capabilities and growth potential.
[Brokerage Focus] Sinolink: The actual geopolitical risk in the Innovative Drugs Sector is low. In the second half of the year, it is recommended to focus on left-side reversals.
Jinwu Finance | Sinolink's Research Reports indicate that the external tariff environment is changing rapidly, and the pharmaceutical Sector has good risk resistance and growth potential. The geopolitical risk in the Innovative Drugs Sector is very low, and there are opportunities for domestic substitution in Blood Products, Medical Device, and instruments. A reversal in the left-side Sector is imminent after the first quarter report, and attention is recommended. The firm states that in the second half of the year, attention should be given to the left-side reversal, as performance gradually recovers and the fundamentals improve. Focus on the individual stocks in Generic Drugs, chain pharmacies, Medical Device, and Traditional Chinese Medicine that are experiencing difficulties. Throughout the year, it is advised to continuously focus on the main line of Innovative Drugs and semi-Innovative Drugs; additionally, in the short term, attention should be paid to the fluctuations in tariffs regarding Blood Product
SKB Biopharmaceutical Gets US FDA Clinical Trial Clearance for Anti-Tumor Drug; Shares Jump 6%
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}